Abivax S.A.
AAVXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $449 | $482 | $121 | $472 |
| - Cash | $144 | $252 | $27 | $61 |
| + Debt | $97 | $59 | $47 | $53 |
| Enterprise Value | $402 | $289 | $140 | $464 |
| Revenue | $11 | $5 | $5 | $0 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Gross Profit | $11 | $4 | $5 | -$0 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| EBITDA | -$172 | -$133 | -$53 | -$39 |
| % Margin | -1,592.7% | -2,882.6% | -1,163.3% | -104,697.3% |
| Net Income | -$176 | -$148 | -$70 | -$41 |
| % Margin | -1,633.1% | -3,197.1% | -1,524% | -111,775.7% |
| EPS Diluted | -2.8 | -3.43 | -3.13 | -2.47 |
| % Growth | 18.4% | -9.6% | -26.7% | – |
| Operating Cash Flow | -$154 | -$97 | -$66 | -$46 |
| Capital Expenditures | -$1 | -$0 | -$4 | -$2 |
| Free Cash Flow | -$155 | -$97 | -$70 | -$47 |